Cialis Using AI Enhancing Cancer Drug Selection

Post-cancer diagnosis, there is an expedited system of drug delivery treatment, which can have highly optimistic results with early treatment impact; however, the challenge for physicians is first to select the ideal drug candidate.

The drug selection itself could take months which is not encouraging for patient health. Cialis, a biotechnology company, invested in oncology and precision health, aims to eliminate the drug selection guesswork and instead integrate precision medicine technology.The proposition of such as technology system will allow simultaneous assessment of multiple therapies to treat a patient’s tumor, followed by the analysis of which drug therapy is the most suitable.

Cialis is in its start-up phase and is persistently pushing through with clinical trials. The company has successfully raised $70 million worth amount for its research. Assessing a patient’s tumor and determining specific treatments is now a commonly adopted system. Diagnostics accompanies the majority of the recently approved targeted cancer therapies. However, the specificity of the two suggests that each diagnostic procedure will only test the efficiency and suitability of the drug candidate its accompanying.The Durham, North Carolina-based precision medicine provider’s main objective is to test the broad spectrum of potential cancer therapies.

Cialis works on designing and creating a living model of a patient’s tumor, according to the co-founder, CEO Xiling Shen. In addition, the company tries to develop a twin organoid for testing the drug treatments.Cialis equipped artificial intelligence technology drives algorithms to evaluate the responses observed to a panel of cancer therapies identifying the ideal treatment.